Language:

A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease

The New England journal of medicine, 2021-07, Vol.385 (1), p.35-45 [Peer Reviewed Journal]

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;COPYRIGHT 2021 Massachusetts Medical Society ;info:eu-repo/semantics/openAccess ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2032441

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease
Author: Schuppan, Detlef ; Mäki, Markku ; Lundin, Knut E.A ; Isola, Jorma ; Friesing-Sosnik, Tina ; Taavela, Juha ; Popp, Alina ; Koskenpato, Jari ; Langhorst, Jost ; Hovde, Øistein ; Lähdeaho, Marja-Leena ; Fusco, Stefano ; Schumann, Michael ; Török, Helga P ; Kupcinskas, Juozas ; Zopf, Yurdagül ; Lohse, Ansgar W ; Scheinin, Mika ; Kull, Karin ; Biedermann, Luc ; Byrnes, Valerie ; Stallmach, Andreas ; Jahnsen, Jørgen ; Zeitz, Jonas ; Mohrbacher, Ralf ; Greinwald, Roland
Subjects: Adverse events ; Allergy ; Atrophy ; Biopsy ; Celiac disease ; Diarrhea ; Diet ; Disease ; Dosage ; Drug dosages ; Drug therapy ; Endoscopy ; Enzyme inhibitors ; Epithelial cells ; Gastroenterology ; Gastroenterology General ; Glutamine ; Gluten ; Health aspects ; Hyperplasia ; Immunology ; Immunology General ; Laboratories ; Lymphocytes ; Lymphocytes T ; Morphology ; Mucosa ; Nausea ; Nutrition ; Patient outcomes ; Patients ; Peptides ; Placebos ; Quality of life ; Questionnaires ; Small intestine ; Testing ; Transglutaminase 2 ; Transglutaminases ; Villus ; Vomiting
Is Part Of: The New England journal of medicine, 2021-07, Vol.385 (1), p.35-45
Description: In a phase 2 proof-of-concept trial, patients with celiac disease controlled on a gluten-free diet were assigned to one of three dose levels of ZED1227 (a selective transglutaminase 2 inhibitor) or placebo. Patients were challenged with 3 g of gluten daily for 6 weeks. Comparison of duodenal-biopsy samples between baseline and 6 weeks showed that ZED1227 attenuated gluten-induced mucosal damage.
Publisher: Boston: Massachusetts Medical Society
Language: English;Norwegian
Identifier: ISSN: 0028-4793
EISSN: 1533-4406
DOI: 10.1056/NEJMoa2032441
Source: ProQuest One Psychology
NORA Norwegian Open Research Archives
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease

Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;COPYRIGHT 2021 Massachusetts Medical Society ;info:eu-repo/semantics/openAccess ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2032441

Searching Remote Databases, Please Wait